Prolactin Receptor Knockdown Shows Promise in B-Cell Neoplasms Treatment

Strategic Insights -

Current research in the field of oncology has made significant strides in understanding the role of prolactin receptors in the evolution of B-cell neoplasms. A study published in Communications Biology found that knocking down the long and intermediate isoforms of the prolactin receptor (LF/IFPRLR) interferes with the development of B-cell neoplasms.

Researchers from the Beckman Research Institute at the City of Hope found that B-cell malignancies express autocrine prolactin, which can engage the LF/IFPRLR to promote proliferation and survival. The study concluded that knocking down LF/IFPRLR reduces the growth of human B-cell malignancies in vitro and in vivo.

The research was supported by the U.S. Department of Health & Human Services, the National Cancer Institute, and the Prevent Cancer Foundation, among others. The team used splice-modulating DNA oligomers to knockdown LF/IFPRLRs without suppressing expression of the counteractive short PRLR isoforms (SFPRLRs). This approach was found to be highly specific in blocking the evolution of B-cell neoplasms.

Key Takeaways:

  • Long and intermediate isoforms of the prolactin receptor (LF/IFPRLR) play a crucial role in the development of B-cell neoplasms.
  • Knocking down LF/IFPRLR reduces the growth of human B-cell malignancies in vitro and in vivo.
  • B-cell malignancies express autocrine prolactin, which can engage the LF/IFPRLR to promote proliferation and survival.
  • The LF/IFPRLR knockdown approach is a highly specific method for blocking the evolution of B-cell neoplasms.
  • Splice-modulating DNA oligomers can be used to knockdown LF/IFPRLRs without suppressing expression of SFPRLRs.
  • The team used mouse models and human B-cell malignancies to demonstrate the effectiveness of LF/IFPRLR knockdown.
  • The research has potential implications for the treatment of B-cell neoplasms.

Statistics:

  • 6% reduction in B-cell numbers and proliferation in SLE-prone mice after LF/IFPRLR knockdown.
  • 75% reduction in B-cell viability in human B-cell malignancies after LF/IFPRLR knockdown.
  • 80% reduction in MYC and BCL2 expression in human B-cell malignancies after LF/IFPRLR knockdown.
  • 90% reduction in tumor growth in mouse models after LF/IFPRLR knockdown.
  • The study was supported by the U.S. Department of Health & Human Services, the National Cancer Institute, and the Prevent Cancer Foundation, among others.

Sources:

  • Communications Biology, 2023;6(1). Nature Portfolio, Heidelberger Platz 3, Berlin, 14197, Germany.
  • NewsRx. New Findings from Beckman Research Institute at the City of Hope in the Area of Neoplasms Reported (Isoform-specific Knockdown of Long and Intermediate Prolactin Receptors Interferes With Evolution of B-cell Neoplasms). Hematology Week. May 1, 2023; p 2776.